|
Безопасность и качество пищевых продуктов
|
|
|
| |
Online help Terminology
This database contains the most recent information on maximum residue levels for veterinary drugs as recommended by JECFA. All monographs published in the FAO Food and Nutrition Papers 41 can be accessed in an electronic format. These monographs are available only in English although some parts of the database, the query page as well as the background information are provided in English, French, Spanish, Arabic and Chinese.
| Veterinary Drug |
Bovine somatotropins |
| Functional class |
Growth promoter |
| Latest evaluation |
2013 |
| JECFA meeting |
78 |
| ADI |
Not specified |
| ADI status |
Full |
| Residue monographs |
|
| Marker residue |
|
Maximum residue limits (MRL) recommended |
| Cattle | Fat | Not Specified | F | | Cattle | Kidney | Not Specified | F | | Cattle | Liver | Not Specified | F | | Cattle | Milk | Not Specified | F | | Cattle | Muscle | Not Specified | F |
|
| Other remarks |
|
| Summary of the evaluation |
The Committee concluded that rbSTs can be used without any appreciable health risk to consumers. This conclusion was based on the following factors: - the insignificant changes in the quantities of milk discarded due to the detection of residues during testing after the introduction of rbSTs into commercial use and pid=63155; - the low levels of residues of rbSTs and IGF-I in milk and pid=63155; - the degradation of IGF-I in the gut and its naturally high levels in the gastrointestinal secretions and pid=63155; - the extremely low levels of IGF-I ingested from milk when compared to endogenous production and pid=63155; - the lack of evidence that rbSTs stimulate the expression of retroviruses and pid=63155; - the lack of information directly linking treatment with rbSTs and BSE and pid=63155; and - the absence of significant changes in the composition of milk from cows treated with rbSTs that may contribute to the additional risk of development of insulin-dependent diabetes mellitus. The Committee reaffirmed its previous ADI and MRLs "not specified" for somagrebove, sometribove, somavubove and somidobove. TRS 888 JECFA78: The Committee reaffirmed its previous decision on ADIs and MRLs not specified for somagrebove, sometribove, somavubove and somidobove. |
|
|
|